Collaboration and Progress at EASL Liver Cancer Summit 2025
From the 20th until the 22nd of February, DiCE attended the EASL Liver Cancer Summit in Paris, France. We had several inspiring meetings with repre...
DiCE Helps Shape New Liver Transplant Recommendations for Liver Cancer
Liver transplantation offers new hope for patients with liver cancer. DiCE has played a key role in shaping the most recent recommendations, which ...
Advancing Liver Cancer Care: Highlights from the BCLC 2024 Meeting
On November 25th and 26th, DiCE virtually attended the Barcelone Clinic Liver Cancer (BCLC) annual conference, which was titled “Forging a Multid...
Hepatocellular Carcinoma Prevention & Diagnosis: DiCE Publishes Project Results
DiCE’s mapping research project on HCC prevention and diagnosis in Europe reveals rising incidence and mortality rates. The results, published du...
HCC Prevention and Diagnosis Mapping Survey
DiCE’s ongoing research project aimed at mapping the status quo in the prevention and diagnosis of hepatocellular carcinoma (HCC) across the ...
DiCE is a Partner in HoloSurge: a Horizon Grant-Winning Project on Holographic Surgical Planning
DiCE is a partner in the HoloSurge project, which was awarded a Horizon Europe grant to improve surgical planning with hologram technology. One of ...
Extending the Liver Cancer Index: HCC Prevention and Diagnosis Mapping
DiCE is launching its research project to map the status quo in preventing and treating hepatocellular carcinoma (HCC) across the EU. We will creat...
COR2ED’s New Resources on Advanced HCC
COR2ED is an independent medical education company that develops impactful educational programmes within specific therapeutic areas. They have rece...
ASCO GI Highlights – Positive Data in Earlier Stage HCC Results
The American Society for Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) was held in San Francisco, USA 18-20 January this year. At ...
EU Commission Approval of Tibsovo® (Ivosidenib) in IDH1-mutated Cholangiocarcinoma
The European Commission approved the use of Tibsovo® (Ivosidenib) as monotherapy for the treatment of locally advanced or metastatic cholangiocarc...